# Progress Note 04 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: George H. W. Bush (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML018-SYN-TD
- Date: 1991-09-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Douglas Whitford, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Four-month review: levothyroxine dose and the anticoagulation decision. **S**

## History of present illness

Mr. Bush returns eight weeks after starting levothyroxine 75 mcg daily. His tiredness and constipation are better, and he feels cold only occasionally. He took metoprolol 25 mg daily for eight weeks and finished the taper this week. He wore the 14-day ECG patch for the two weeks ending four days ago, with no palpitations. He takes apixaban twice daily with no bleeding. He runs three miles four days a week without symptoms and has regained his usual weight. He takes levothyroxine alone on an empty stomach each morning. **S**

| Element | Detail |
|---|---|
| Thyroid symptoms | Tiredness and constipation better; occasionally cold |
| Rhythm | No palpitations; 14-day patch completed |
| Medicines | Levothyroxine 75 mcg daily; metoprolol taper completed; apixaban twice daily |
| Activity | Running three miles four days a week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Occasionally cold; energy nearly back to normal; weight back to his usual |
| Cardiovascular | Negative | No palpitations, chest pain, or lightheadedness |
| Gastrointestinal | Negative | Bowels regular |
| Hematologic | Negative | No bleeding or bruising |

4 systems reviewed. **S**

## Current medications

- Levothyroxine 100 mcg oral tablet, one tablet by mouth daily before breakfast **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/76 mmHg; pulse 62 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 90.2 kg; BMI 25.5 kg/m². All vital signs are synthetic.

TSH: 6.4 mIU/L (high); Free T4: 0.9 ng/dL. All results are synthetic.

## Change since baseline

- TSH: 0.005 mIU/L (low) at baseline, 6.4 mIU/L (high) at this visit **S**
- Free T4: 3.6 ng/dL (high) at baseline, 0.9 ng/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well and fit |
| Neck | Small, non-tender thyroid |
| Cardiovascular | Regular rhythm at 62 per minute; no murmur |
| Neurological | Reflexes normal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hypothyroidism after radioactive iodine, under-replaced** (E89.0). TSH 6.4 mIU/L, above the target of 0.4 to 4.0, with free T4 0.9 ng/dL in range and mild residual symptoms. **S**
   - Increase levothyroxine to 100 mcg daily.
   - TSH in six weeks.
2. **Paroxysmal atrial fibrillation, in sustained sinus rhythm** (I48.0). The 14-day patch showed sinus rhythm throughout with no atrial fibrillation, now that he is no longer thyrotoxic, and the resting rate is 62 off metoprolol. CHA2DS2-VASc remains 1. The trigger has been treated and sinus rhythm is sustained, so the benefit of continued anticoagulation is small. After discussing stroke and bleeding risks, he chose to stop apixaban. **S**
   - Stop apixaban today.
   - Metoprolol taper completed; no rate-control medicine needed.
   - Check his pulse if he feels palpitations and call the same day for an irregular pulse; anticoagulation will be reconsidered if atrial fibrillation recurs and when his CHA2DS2-VASc reaches 2 at 75.
   - Running and full activity without restriction.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Heart rate and rhythm | Every visit | Completed today | 62 per minute, regular, off metoprolol |
| Examination | Blood pressure | Every visit; target below 130/80 | Completed today | 126/76 mmHg |
| Examination | Weight and BMI | Every visit | Completed today | 90.2 kg, BMI 25.5; back to his usual weight |
| Survey | Atrial fibrillation symptoms | Every visit | Completed today | None |
| Imaging | Ambulatory rhythm monitoring | As symptoms or decisions require | Completed today | 14-day ECG patch: sinus rhythm throughout; no atrial fibrillation or flutter |
| Survey | CHA2DS2-VASc and HAS-BLED | Yearly and with any change in clinical status | Completed today | Reassessed for the anticoagulation decision: CHA2DS2-VASc 1, HAS-BLED 1 |
| Medication safety | Anticoagulation decision | With any change in clinical status | Completed today | Apixaban stopped by shared decision after sustained sinus rhythm with the trigger treated |
| Laboratory | Creatinine and eGFR on apixaban | At baseline and at least yearly | Not indicated | Apixaban stopped today |
| Self-management | Alcohol, tobacco, and physical activity | Every visit | Completed today | Alcohol rarely; never used tobacco; running about 200 minutes a week |
| Survey | Sleep apnea symptom screen | At diagnosis and at least yearly | Up to date | Negative two months ago |
| Laboratory | TSH after a levothyroxine dose change | Four to eight weeks after each dose change | Completed today | TSH 6.4 mIU/L, free T4 0.9 ng/dL, eight weeks after starting 75 mcg |
| Survey | Hypothyroid and overtreatment symptoms | Every visit during titration | Completed today | Mild residual cold intolerance; no palpitations, tremor, or weight loss |
| Laboratory | TSH at six months once stable, then yearly | After the dose is stable | Due | Dose changed today; TSH in six weeks first |

## Goal progress

- Resting heart rate below 110 per minute without palpitations while thyrotoxic. Outcome by 1991-05-20: Heart rate 72 in sinus rhythm on metoprolol two weeks after intake. **S**
- No atrial fibrillation once no longer thyrotoxic, confirmed by ambulatory monitoring before the anticoagulation decision. Outcome by 1991-09-11: Sinus rhythm throughout a 14-day ECG patch. **S**
- TSH within 0.4 to 4.0 mIU/L on levothyroxine. In progress; target 1991-10-16. **S**
- Back to running three miles several days a week without symptoms. Outcome by 1991-09-11: Running three miles four days a week without palpitations. **S**

## Medication changes

- Stopped: Metoprolol succinate extended-release 25 mg oral tablet, one tablet by mouth daily (taper) **S**
- Stopped: Apixaban 5 mg oral tablet, one tablet by mouth twice daily (started in hospital) **S**
- Stopped: Levothyroxine 75 mcg oral tablet, one tablet by mouth daily before breakfast **S**
- Started: Levothyroxine 100 mcg oral tablet, one tablet by mouth daily before breakfast **S**

## Guideline basis

- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023), American College of Cardiology, American Heart Association, American College of Chest Physicians, and Heart Rhythm Society (Circulation 2024;149(1):e1-e156)
- Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement (2014), American Thyroid Association (Thyroid 2014;24(12):1670-1751)
- CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026), Aether Forge

## Follow-up

- TSH in six weeks; annual wellness visit next month. **S**
- Next scheduled visit 1991-10-16: subsequent annual wellness visit. **S**
